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Accelerated biological ageing in HIV-infected
individuals in South Africa: a case–control study
Sophia Pathaia,b, Stephen D. Lawnb,c, Clare E. Gilberta,
Dagmara McGuinnessd, Liane McGlynnd, Helen A. Weisse,
Jennifer Portd, Theresa Christd, Karen Barclayd, Robin Woodb,
Linda-Gail Bekkerb and Paul G. Shielsd
Objectives: Little is known about the impact of HIV infection on biological ageing in
sub-Saharan Africa. The study aimed to assess biological ageing in South African HIV-
infected adults and HIV-seronegative individuals using two validated biomarkers,
telomere length and CDKN2A expression (a mediator of cellular senescence).
Design: A case–control study.
Methods: Two hundred and thirty-six HIV-infected adults aged at least 30 years and
250 age and sex frequency matched HIV-seronegative individuals were recruited from
clinics in township communities in Cape Town. Biological ageing was evaluated by
measurement of telomere length and CDKN2A expression in peripheral blood leuko-
cytes.
Results: The median ages of the HIV-infected and HIV-seronegative participants were
39 and 40 years, respectively. Among HIV-infected participants, 87.1% were receiving
antiretroviral therapy (ART), their median CD4þ cell count was 468 cells/ml and 84.3%
had undetectable viral load. Both biomarkers were validated against chronological age
in HIV-seronegative individuals. Telomere length was significantly shorter in HIV-
infected individuals than in HIV-seronegative individuals (mean relative T/S ratio
SE:0.910.007 vs. 1.070.008, P<0.0001). CD2NKA expression was higher in
HIV-infected participants than in HIV-seronegative individuals (mean expression:
0.450.02 vs. 0.360.03, P¼0.003). Socioeconomic factors were not associated
with biological ageing in HIV-infected participants. However, in participants on ART
with undetectable viral load, biomarker levels indicated greater biological ageing in
those with lower current CD4þ cell counts.
Conclusion: Telomere length and CDKN2A expression were both consistent with
increased biological ageing in HIV-infected individuals. Prospective studies of the
impact of HIV on biological ageing in sub-Saharan Africa are warranted.
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Introduction
HIV-infected individuals are at an increased risk of age-
related non-AIDS morbidity and mortality compared
with HIV-uninfected persons [1]. It is speculated that
HIV-infected individuals may not only be ageing
chronologically but also undergoing accelerated bio-
logical ageing mediated by increased cellular senescence
[2]. Chronological age is an imprecise measure of
biological ageing, due to inter-individual differences in
rates of ageing. The disconnection between chronologi-
cal age and lifespan has led to a search for effective and
validated biomarkers of ageing (BoA), defined as
‘biological parameters of an organism that either alone
or in some multivariate composite will better predict
functional capability at some late age, than will
chronological age’ [3].
Data from industrialized countries on the impact of HIV
on accelerated ageing may be confounded by differential
risk exposure by HIV status to risk factors, such as
smoking and alcohol consumption. Moreover, lower
socioeconomic status and poor diet are also associated
with accelerated biological ageing [4]. Thus, the NIH
Office of AIDS Research has highlighted the need for
carefully designed studies of HIV and ageing that takes
these factors into account [5]. Assessment of biological
ageing in HIV infection in sub-Saharan Africa may also be
influenced by coexisting morbidities, malnutrition, a high
prevalence of enteric pathogens and opportunistic
coinfections and epigenetic variation [6,7]. Thus, data
related to biological ageing and HIV obtained from well
resourced settings may not be directly translatable to
African populations. However, few data are available from
sub-Saharan Africa populations [8] where three million
people aged 50 years and older are living with HIV [9]. If
premature biological ageing is associated with HIV, then
age-relatedmorbidity in HIV-infected individuals is likely
to place a significant burden on healthcare systems in sub-
Saharan Africa.
Telomeric DNA length is a widely used BoA. Telomeres
are nucleoprotein complexes at the ends of eukaryotic
chromosomes. Their DNA component shortens with
somatic cell division, and upon reaching a critically short
length, a DNA damage signal leads to cell cycle arrest,
resulting in replicative senescence [10,11]. Telomere
shortening is associated with increasing chronological
age, and a wide range of diseases, including cardiovascular
disease [12] and renal dysfunction [13]. Telomere attrition
is affected by psychosocial confounders, genetics and
potentially by nucleoside reverse transcriptase inhibitors
(NRTIs) [14]. Expression levels of the cell cycle regulator
CDKN2A may represent a more robust BoA [15].
CDKN2A acts as a tumour suppressor and maintains
cells in a state of growth arrest both in replicative and
stress-induced premature senescence. Increasing levels
of CDKN2A transcriptional expression occur with
increasing age both in solid organs and peripheral blood
leukocytes (PBLs) [16]. In the former, increasing
CDKN2A expression correlates directly with decreasing
function.
This cross-sectional study conducted in South Africa was
undertaken to provide a rapid assessment of whether there
was evidence that HIV-infected individuals had advanced
biological ageing compared with HIV-seronegative
individuals by comparing telomere length and CDKN2A
expression.
Materials and methods
Ethics statement
The study was approved by the Ethics Committees of the
London School of Hygiene and Tropical Medicine and
the University of Cape Town Faculty of Health Sciences,
and was adhered to the tenets of the Declaration of
Helsinki. Written informed consent was obtained from
all participants.
Study participants
HIV-infected individuals aged at least 30 years were
enrolled from a community-based HIV treatment centre
in Nyanga district in Cape Town [17]. All participants had
a confirmed serological diagnosis of HIVand either about
to commence antiretroviral therapy (ART; ART-naive)
or were already on first-line ART. HIV-seronegative
participants were recruited using frequency-matching by
sex and 5-year age categories. HIV-seronegative indi-
viduals were enrolled from participants confirmed to be
HIV-seronegative attending an HIV prevention trials
centre (Emavundleni Centre). These two centres were
chosen, as attendees were drawn from the same
community and therefore likely to have similar
sociodemographic characteristics.
Data and sample collection
Sociodemographic information and medical history were
obtained by questioning participants in their first
language (Xhosa or English). Data collected included
factors known to affect ageing [e.g. indoor/outdoor
occupation as a proxy for ultraviolet (UV) exposure].
Clinical information was available relating to current and
nadir CD4þ cell counts, peak and current HIV plasma
viral load and WHO clinical status. Venous blood was
collected at the time of participant interview to measure
telomere length and CDKN2A expression in PBL.
DNA/RNA extraction
DNA was extracted from PBLs using the Maxwell
Automated Purification System according to manufac-
turer’s instructions (Promega, Madison, Wisconsin,
USA). DNA concentration and purity was quantified
by Nanodrop Spectrophotometer (ThermoFisher
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Scientific, Waltham, Massachusetts, USA). RNA was
extracted using Trizol reagent (Invitrogen, Life Tech-
nologies, Grand Island, New York, USA) following
manufacturer’s guidelines. DNA/RNA extraction was
performed in Cape Town and samples shipped on dry ice
to the University of Glasgow.
Telomere length determination
Telomere lengths were determined by quantitative PCR
(qPCR) following the method of Cawthon [18].
Telomere length determination was performed blindly
using a Roche Light Cycler (Roche Diagnostics,
Indianapolis, Indiana, USA) LC480. Briefly, telomere
length analyses were performed in triplicate for each
sample, using a single-copy gene amplicon primer set
(acidic ribosomal phosphoprotein, 36B4) and a telomere-
specific amplicon primer set [19]. Quality control
parameters for the amplifications comprised a cut-off
of 0.15 for the standard deviation (SD) of the threshold
cycle (Ct) for sample replicates. At a SD above 0.15, the
sample was reanalysed. The average SD across plates was
0.05. Relative telomere length was estimated from Ct
scores using the comparative Ct method after confirming
that telomere and control gene assays yielded similar
amplification efficiencies. This method determines the
ratio of telomere repeat copy number to single copy gene
number (T/S) ratio in experimental samples relative to a
control sample DNA. This normalized T/S ratiowas used
as the estimate of relative telomere length (Relative T/S).
The interassay variation was assessed by comparing the
relative telomere estimates (T/S ratio) estimates across
assays for the positive controls, assayed on every assay
plate. The average interassay coefficient of variance was
0.6% for telomere length and 0.23% for 36B4, with
coefficient of variances comparable to previous data from
this laboratory [20,21].
CDKN2A expression determination
Relative quantitative real-time PCR (qRT-PCR) was
used to estimate mRNA levels corresponding to the
candidate senescence associated gene CDKN2A in line
with established methodology [19,22]. Expression levels
were measured against a reference hypoxanthine phos-
phoribosyltransferase (HPRT) housekeeping gene on an
ABI Prism(R) 7500 Sequence Detection System.
Sequences of human TaqMan Primer/Probe sets were
designed by Primer Express algorithm (Applied Biosys-
tems, Austin, Texas, USA). The comparative threshold
cycle method (DDCT) [23] was employed to quantify
relative gene expression.
Statistical analysis
Analyses were performed using Stata 12 (Stata Corp,
College Station, Texas, USA). Clinical and biochemical
data were summarized as the median with interquartile
range (IQR) or mean with standard error (SE), as
appropriate. Analyses were conducted on log10-trans-
formed values of telomere length and mean CDKN2A
expression to satisfy the assumption of normally
distributed residuals. Results are displayed back-trans-
formed to the original scale. Univariable analyses were
performed to assess the relationships between mean
telomere length, CDKN2A expression, HIV status and
other clinical/demographic categories. Multivariable
linear regression was used to examine the relationships
of biomarker expression with HIV status adjusting for
confounders identified in the univariable analysis and for
a priori defined confounders (age and sex).
Results
Participant characteristics
Characteristics of the 236 HIV-infected individuals and
250 age/sex frequency matched HIV-seronegative
individuals are reported in Table 1. All participants were
of African ancestry. Telomere data were available for all
participants, and CDKN2A data for 444 participants
(91.4%). The majority (75%) of the study population was
female. The median age of the HIV-infected population
was 39 years (IQR 35–46 years), similar to the HIV-
seronegative group (median 40 years (IQR 35–49 years))
(P¼ 0.17). HIV-infected participants tended to be of
higher socioeconomic status and were less likely to smoke
or consume alcohol (Table 1). Cases also had a lower
mean BMI and were more likely to have current or
previous tuberculosis (TB) than HIV-seronegative indi-
viduals. Overall, 87.1% of HIV-infected participants were
receiving ART and the current CD4þ cell count among
these participants was 468 cells/ml (IQR 325–607 cells/
ml) and 84.3% had an undetectable viral load
(<50 copies/ml). All participants on ART received a
regimen that contained an NRTI.
Biological age and chronological age in
HIV-seronegative individuals
Telomere length and CDKN2A levels were validated
against chronological age in HIV-seronegative individuals.
As expected, there was a negative association between
chronological age and telomere length (Pearson r¼0.13,
P¼ 0.05), and a positive association with CDKN2A
expression (r¼ 0.16, P¼ 0.02). The relationship between
CDKN2A expression and age was similar in men and
women. However, for telomere length, age-related
attrition was somewhat greater in men than in women,
but this difference did not reach statistical significance
(r¼0.25 vs. r¼0.09, P-interaction¼ 0.13).
Biological age and HIV status
Telomere length was significantly shorter in HIV-infected
individuals than in HIV-seronegative individuals [mean
relative T/S ratio (Rel T/S) SE: 0.91 0.007 vs.
1.07 0.008, P< 0.0001, Fig. 1a]. Telomere length
decreased with chronological age in HIV-infected
individuals (r¼0.15, P¼ 0.03). Mean CDKN2A
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expression was higher in HIV-infected participants
than in HIV-seronegative individuals (0.45 0.02 vs.
0.36 0.03, P¼ 0.003, Fig. 1b, Table 2), and there was
little evidence of correlation between chronological age
and CDKN2A expression in HIV-infected individuals
(r¼ 0.09, P¼ 0.17). No interactions were detected with
HIV status when assessing the relationship between
biomarkers and chronological age (data not shown).
Among the HIV-infected patients, there was no evidence
that either telomere length or CDKN2A expression was
associated with ART status (P¼ 0.71 telomere length;
P¼ 0.80 CDKN2A; Table 2).
Among the 172 participants on ART with viral
suppression, current CD4þ cell count was positively
associated with telomere length and negatively associated
with CDKN2A expression (P-trend¼ 0.02 telomere
length; P-trend¼ 0.05 CDKN2A; Table 3). There was
no evidence of an association between these BoA and
CD4þ cell count in patients with detectable viral load
(data not shown).
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Table 1. Characteristics of study population.
Variable
HIV-infected
participants (236) % (n)
HIV-seronegative
participants (250) % (n) P
Age (years) 39 (35–46)a 40 (35–49)a 0.17
Age (years) by group
30–39 50.4 (119) 46.4 (116)
40–49 32.6 (77) 32.0 (80) 0.41
>50 17.0 (40) 21.6 (54)
Male sex 25.4 (60) 24.0 (60) 0.72
Education
<High school 11.9 (28) 17.6 (44) 0.08
High school or tertiary education 88.1 (208) 82.4 (206)
Income
<US$ 125/month 56.8 (134) 67.2 (168) 0.02
>US$ 125/month 43.2 (102) 32.8 (82)
Housing
Informal 47.9 (113) 40.4 (101) 0.10
Formal 52.1 (123) 59.6 (149)
Water supply
Shared 75.0 (177) 74.0 (185) 0.80
Own 25.0 (59) 26.0 (65)
Alcohol (amount per week)
Nil 69.5 (164) 56.4 (141)
Up to 1 l/week 20.3 (48) 21.6 (54) 0.001
>1 l/week 10.2 (24) 22.0 (55)
Duration of smoking (years)
Nil 84.8 (200) 72.0 (180)
<10 years 5.1 (12) 12.8 (32) 0.002
>10 years 10.2 (24) 15.2 (38)
Illicit drugs
Never taken 97.4 (222) 98.0 (240)
Ever taken 2.6 (6) 2.0 (5) 0.67
BMI (kg/m2) 27.80.4 31.50.6 <0.0001
Comorbidity (including hypertension)
None 64.4 (152) 55.2 (138)
One or more 35.6 (84) 44.8 (112) 0.04
TB status
No history 32.6 (77) 87.6 (219)
Current 4.2 (10) 0.4 (1) <0.0001
Previous 63.1 (149) 12.0 (30)
HIV characteristics % (n) or median (IQR)
WHO stage
1/2 27.1 (67)
3/4 72.3 (181)
ART naive 12.9 (32)
CD4þ cell count in ART-naive group (n¼32) 182 (84–202)
Log10VL in ART-naive group (n¼21) 4.88 (4.21–5.18)
Current CD4þ cell count in ART group (cells/ml) 468 (325–607)
Nadir CD4þ cell count in ART group 128 (76–171)
% with undetectable VLb in ART group (cells/ml) 84.3 (172)
Peak log10VL in ART group 4.56 (3.84–4.98)
Duration of ART, months 58 (34–75)
ART, antiretroviral therapy; TB, tuberculosis; VL, viral load.
aValues expressed as median (interquartile range).
bUndetectable VL refers to VL <50 copies/ml.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Biological age and sociodemographic
characteristics
As sociodemographic characteristics may be associated
with biological ageing [4,24], we analysed their
association with the two BoA, stratified by HIV status
(Table 4a,b). HIV-infected participants aged at least
50 years had significantly shorter telomeres than HIV-
seronegative individuals in the same age group (mean
RelT/S 0.84 vs. 1.01, P¼ 0.03; Table 4a). There were no
significant associations between telomere length and
other sociodemographic variables for HIV-infected
participants. In HIV-seronegative individuals, an associ-
ation with alcohol consumption and telomere length was
detected, with those who did not consume alcohol and
those who consumed more than 1 l/week having the
shortest telomere lengths (P¼ 0.04) (Table 4a). For
CDKN2A expression, the only evidence of an association
was among HIV-seronegative individuals, in whom
CDKN2A expression was higher among those with
lower incomes than among those with higher incomes
(mean RelT/S 0.39 vs. 0.30, P¼ 0.03; Table 4b).
Discussion
Levels of two validated biomarkers of ageing (telomere
length and CDKN2A expression) were found to be
consistent with increased biological ageing in South
African HIV-infected individuals compared with age and
sex-matched HIV-seronegative controls. This important
finding is supported by our previous observations in this
same study population that HIV infection is associated
with increased frequency of a frailty phenotype [25], and
changes in retinal vessel calibre, lens density and corneal
endothelial cells that are consistent with increased
biological ageing [26–28]. Among patients receiving
ART and in whom plasma viral load was suppressed, the
biological ageing estimated by both biomarkers was
greatest in those with low current CD4þ cell counts.
Although long-term prospective cohort studies will be
required to definitively characterize the impact of HIVon
biological ageing in sub-Saharan Africa, the combination
of these case–control biomarker data and the existing
frailty and ocular phenotypic data provide a strong
evidence base on which to justify future long-term
studies.
Both biomarkers were strongly associated with chrono-
logical age in HIV-seronegative individuals, validating
their use as BoAs. Reduced telomere length is associated
with markers of low socioeconomic status in industri-
alized countries [4,24]. Lower income was associated
with increased CDKN2A expression in HIV-seronega-
tive individuals, but socioeconomic factors were not
associated with either BoA in HIV-infected participants.
Adjustment for socioeconomic factors did not alter
estimates of BoA between HIV-infected participants and
HIV-seronegative individuals, suggesting that HIV
infection, rather than social deprivation, is the main
driver of biological ageing in this population.
Ageing reflects an accumulation of multiple molecular
deficits in varying organ systems [29]. Interindividual
differences in rates of ageing have prompted the search for
informative biomarkers of biological ageing. Measure-
ment of telomere length in PBLs is the standard method
of evaluating biological ageing in epidemiological studies,
with changes in PBL telomere length in effective
synchrony with changes in telomere length in solid
organs, thus providing a suitable surrogate for biological
age in the whole organism [30,31]. However, there is
potential for confounding by methodological and design
difference between studies [15]. The number of
techniques available for telomere length measurement
highlights that no one technique is entirely satisfactory
[32]. Southern blotting of terminal restriction fragments,
single telomere length analysis (STELA) and real-time
qPCR (qPCR) may also be used to assess telomere length
in PBLs. We chose to use qPCR, as it is the most suitable
methodology for high-throughput analyses [15,33].
Although interassay comparisons are very good (as
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Fig. 1. Assessment of biomarkers (telomere length and
CDKN2A) in peripheral blood leukocytes. (a) Measurement
of telomere length in peripheral blood leukocytes in HIV-
seronegative and HIV-infected individuals. Telomere length
measured as mean relative T/S ratio: RelT/S SE: 0.910.007
vs. 1.070.008, P<0.0001. (b) Measurement of CDKN2A
expression in HIV-seronegative and HIV-infected individuals.
Relative expression 0.45 0.02 vs. 0.360.03, P¼0.003.
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evidenced by our coefficient of variance of 0.6%), intra-
laboratory comparisons can be poor [34]. Logistical and
budgetary constraints precluded assessment of telomere
length in T-cell subsets, a methodology to address
telomere dynamics advocated previously for investigation
in the context of HIV infection [35]. Although we
acknowledge that this methodology would give a higher
resolution data set, the primary aim of this study was to
provide preliminary data to inform future work, and
assessment of telomere length in PBLs has been the
approach used by others in this field [36,37].
In view of these methodological issues, we elected to
measure an additional BoA, CDKN2A. CDKN2A
expression increases with increasing chronological age
in PBLs and solid organs [16,19,22], and it functions as a
direct marker of cellular growth arrest [16]. CDKN2A
represents a superior BoA to telomere length when
judged by the Baker and Sprott criterion [3]. It can be a
stronger predictor of function than chronological age and
displays less interindividual variation [19,22]. CDKN2A
expression was substantially greater in HIV-infected
adults than in age-matched HIV-seronegative individuals.
As well as functioning as a tumour suppressor, CDKN2A
is also a component of stress-induced premature
senescence [38], which prevents T-cell replication
following acute insult [39]. The decoupling of the
relationship between CDKN2A expression and chrono-
logical age in HIV-infected individuals is a direct
consequence of HIV-associated premature T-cell senes-
cence [2], and lack of further T-cell replication with HIV
infection. Nelson et al. [40] found that ART-naive
individuals had higher levels of CDKN2A expression
than HIV-seronegative individuals, and suggested that
active HIV replication accounted for elevated expression.
Our data show that with viral suppression and ART, high
levels of CDKN2A are still detectable. Thus, high rates of
HIV replication are not a prerequisite for continued,
elevated expression of this biomarker.
Both biomarkers were significantly associated with
current CD4þ cell count in those receiving ART in
whom viral load was undetectable. Increased CDKN2A
expression was associated with lower CD4þ cell counts,
2380 AIDS 2013, Vol 27 No 15
Table 2. Association of HIV states with telomere length and CDKN2A expression.
Clinical group N
Telomere length
Mean Rel T/S (95% CI) P N
Mean CDKN2A
expression (95% CI) P
HIV-seronegative
250 1.07 (1.04–1.11) <0.0001a 217 0.35 (0.32–0.39) 0.006a
HIV-infected;
On ART 204 0.91 (0.87–0.94) 199 0.45 (0.40–0.50)
HIV-infected; ART-naive
32 0.89 (0.81–0.98) 0.71b 28 0.46 (0.34–0.62) 0.80b
ART, antiretroviral therapy; CI, confidence interval.
aP value for HIV-seronegative individuals vs. HIV-infected participants overall.
bP value between HIV group (i.e. on ART and ART-naive).
Table 3. Association of biomarkers with HIV-related covariates.
Variable N¼172
Telomere length
Mean Rel T/S (95% CI) P N¼168
Mean CDKN2A
(95% CI) P
WHO stage
1/2 33 0.89 (0.81–0.97) 32 0.44 (0.35–0.56)
3/4 139 0.92 (0.88–0.96) 0.48 136 0.46 (0.41–0.51) 0.81
Duration of ART (months)
0–36 40 0.86 (0.80–0.93) 0.10M 39 0.51 (0.41–0.63) 0.17M
36–72 80 0.91 (0.87–0.97) 79 0.45 (0.39–0.52)
>72 52 0.95 (0.88–1.01) 50 0.42 (0.35–0.51)
Current CD4þ cell count (cells/ml)
<200 7 0.85 (0.70–1.02) 0.02M 7 0.63 (0.38–1.03) 0.05M
201–350 37 0.83 (0.77–0.91) 37 0.52 (0.42–0.64)
>351 128 0.93 (0.90–0.98) 124 0.43 (0.38–0.48)
Nadir CD4þ cell count (cells/ml)
<200 153 0.91 (0.87–0.94) 0.58 151 0.46 (0.41–0.51) 0.80
>201 19 0.93 (0.83–1.05) 17 0.44 (0.32–0.61)
Peak viral load
<10 000 copies 52 0.92 (0.86–0.99) 51 0.50 (0.42–0.61)
>10 000 copies 120 0.91 (0.87–0.95) 0.68 117 0.44 (0.38–0.48) 0.27
TB status
No history 48 0.91 (0.84–0.97) 47 0.47 (0.39–0.57)
Current /previous history 124 0.91 (0.87–0.95) 0.92 121 0.45 (0.40–0.51) 0.69
Linear regression adjusted for age in participants on ART with suppressed VL (i.e. <50 copies/ml). ART, antiretroviral therapy; CI, confidence
interval; TB, tuberculosis; VL, viral load. MP value test for trend.
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Table 4. (a) Mean telomere length (RelT/S) in HIV-infected participants and HIV-seronegative individuals, adjusted for age.
Variable N
HIV-infected participants
Telomere length
Mean Rel T/S (95% CI) P N
HIV-seronegative participants
Telomere length
Mean Rel T/S (95% CI) P
Age (years)
30–39 119 0.92 (0.88–0.96) 116 1.10 (1.04–1.15)
40–49 77 0.93 (0.88–0.98) 0.11 80 1.09 (1.02–1.15) 0.09M
>50 40 0.84 (0.77–0.91) 54 1.01 (0.94–1.08)
Sex
Male 60 0.92 (0.86–0.99) 60 1.04 (0.97–1.12)
Female 176 0.90 (0.87–0.94) 0.56 190 1.08 (1.04–1.12) 0.30
Income/month (US$)
<US$ 125/month 134 0.91 (0.87–0.95) 168 1.07 (1.02–1.12)
>US$ 125/month 102 0.90 (0.85–0.95) 0.86 82 1.07 (1.00–1.14) 0.94
UV exposure/occupation
Outdoor worker 155 0.90 (0.86–0.94) 0.69 178 1.08 (1.04–1.13) 0.30
Indoor worker 81 0.92 (0.87–0.97) 72 1.04 (0.98–1.12)
Education
<High school 28 0.91 (0.82–1.01) 44 1.04 (0.96–1.11)
High school/college 208 0.91 (0.87–0.94) 0.91 206 1.08 (1.04–1.12) 0.49
Housing
Formal 123 0.91 (0.87–0.96) 149 1.06 1.02–1.11
Informal 113 0.90 (0.86–0.95) 0.69 101 1.09 1.03–1.15 0.77
Duration of smoking
Nil 200 0.91 (0.88–0.95) 180 1.08 (1.03–1.12)
<10 years 12 0.93 (0.80–1.08) 0.36 32 1.07 (0.97–1.17) 0.92
10 years 24 0.85 (0.77–0.95) 38 1.07 (0.98–1.16)
Alcohol (amount per week)
Nil 164 0.92 (0.86–0.96) 0.18M 141 1.08 (1.03–1.13) 0.04
<1 l 48 0.89 (0.82–0.95) 54 1.13 (1.05–1.22)
>1 l 24 0.86 (0.77–0.95) 55 1.00 (0.93–1.08)
BMI (kg/m2)
<25 87 0.88 (0.83–0.93) 0.08 60 1.04 (0.97–1.11) 0.35
25–29.9 71 0.96 (0.90–0.98) 55 1.12 (1.04–1.20)
>30 78 0.90 (0.85–0.95) 135 1.07 (0.98–1.12)
Comorbid condition
No 152 0.91 (0.87–0.95) 138 1.08 (1.04–1.14)
Yes 84 0.90 (0.85–0.95) 0.88 112 1.06 (1.00–1.11) 0.65
TB status
No history 77 0.90 (0.85–0.96) 0.88 219 1.07 (1.03–1.11) 0.71
Current/past 159 0.91 (0.87–0.95) 31 1.09 (0.99–1.20)
(b) Relative CDKN2A expression in HIV-infected participants and HIV-seronegative individuals, adjusted for age.
Variable N
HIV-infected participants
Mean CDKN2A P N
HIV-seronegative participants
Mean CDKN2A P
Age (years)
30–39 113 0.41 (0.36–0.47) 98 0.29 (0.25–0.35)
40–49 74 0.45 (0.38–0.53) 0.04M 70 0.44 (0.37–0.54) 0.006
>50 40 0.54 (0.43–0.68) 49 0.38 (0.30–0.48)
Sex
Male 59 0.42 (0.35–0.50) 53 0.37 (0.30–0.47)
Female 168 0.45 (0.41–0.51) 0.46 163 0.35 (0.31–0.40) 0.71
Income/month (US$)
<US$ 125/month 129 0.43 (0.38–0.48) 145 0.39 (0.34–0.44)
>US$ 125/month 98 0.47 (0.41–0.54) 0.44 72 0.30 (0.23–0.37) 0.03
UV exposure/occupation
Outdoor worker 147 0.45 (0.40–0.50) 155 0.36 (0.32–0.41)
Indoor worker 80 0.45 (0.38–0.52) 0.81 62 0.34 (0.28–0.42) 0.86
Education
<High school 27 0.48 (0.36–0.64) 39 0.34 (0.26–0.44)
High school/college 200 0.44 (0.40–0.49) 0.60 178 0.36 (0.32–0.41) 0.66
Housing
Formal 121 0.44 (0.39–0.50) 126 0.34 (0.30–0.40)
Informal 106 0.45 (0.40–0.52) 0.63 91 0.37 (0.31–0.44) 0.47
Duration of smoking
Nil 192 0.45 (0.40–0.49) 157 0.36 (0.31–0.40)
<10 years 12 0.65 (0.43–0.93) 0.08 27 0.43 (0.31–0.58) 0.23
>10 years 23 0.36 (0.28–0.49) 33 0.30 (0.22–0.43)
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consistent with the finding that CDKN2A expression is
inversely related to T-cell replicative capacity [39].
Telomere length was also shorter in participants on
ARTwith lower current CD4þ cell counts. Thus, levels
of both BoA suggested that lower current CD4þ cell
counts were associated with greater biological ageing.
Human telomerase comprises a reverse transcriptase
sharing homology with the HIV reverse transcriptase
[41]. It is plausible that ART may inhibit its activity,
leading to differences in telomere lengths between ART-
naive and treated groups. Previous studies have produced
inconsistent findings regarding such an association
[36,42,43]. Comparison of levels in treated and ART-
naive groups in our study did not support this potential
mechanism, and furthermore, neither BoAwas associated
with ART duration. It should, however, be noted that
dynamic changes over time in the PBL composition of
the blood during ART may account for some of the
observed effects, reflecting a potential limitation of using
mixed PBLs in this context.
Although we have demonstrated a substantial effect of
HIV infection on biological ageing, estimating the
magnitude of the effect is challenging. One important
reason is because disease states can cause stress-induced
premature senescence [38], leading to acute growth arrest
(in contrast to gradual replicative senescence). Thus, the
‘rate of biological ageing’ may not be accurately predicted
in HIV infection. In other words, HIV-infected
individuals effectively display a biological age observed
in older uninfected individuals due to disease-induced
stress. Therefore, quantification in terms of an effective
biological age difference between infected and uninfected
individuals is problematic, as the component of stress-
induced premature senescence in infected individuals will
be missing in uninfected controls, whereas in turn,
replicative senescence may be accelerated due to disease
stress. Estimation of telomere length as a function of given
chronological age has been quantified [35,44]; however
telomere length as an isolated measure at a given age may
be imprecise, reflecting psychosocial, genetic and
epigenetic confounders. The predictive capability of
CDKN2A in determining effective biological age is
relatively novel [16], and as CDKN2A expression is
related to cellular growth arrest, it may not be subject to
similar attrition phenomena [19,22,33]. Future work
should involve development of methods to establish
quantification of differences in effective biological age in
disease states wherein stasis is involved. Any measure of
the difference in biological age between HIV-infected
and HIV-seronegative individuals will also have to be
viewed in a functional context between these two groups,
wherein differences in biochemical parameters, such as
interleukin-6, CD14 and D-dimer, are also addressed
[45]. Inflammation and activation of coagulation path-
ways are central to the pathophysiology leading to
morbidity. Immune activation is a hallmark of chronic
HIV infection and may be mediated by several
mechanisms: increased pathogen burden as a result of
impaired immunity, chronic viral replication of HIV and
other viruses (e.g. cytomegalovirus, hepatitis viruses) and
microbial translocation of bacterial products across
damaged mucosa (e.g. in the gut). These factors may
also need to be correlated to biomarkers of ageing to fully
elucidate accelerated ageing trajectories in HIV infec-
tion.
A key strength of our study is the inclusion of an age and
sex-matched control group with a similar sociodemo-
graphic profile as the HIV-infected participants. The
hypothesis of accelerated ageing in HIV has received
criticism due to limitations in characterization of
participants, particularly the possibility of differential
exposure to potential risk factors between HIV-infected
and uninfected populations [46]. As the HIVepidemic in
South Africa is generalized and recruitment took place
from the same community, the likelihood of differential
exposure was minimized. The study design means that
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Alcohol (amount per week)
Nil 155 0.45 (0.40–0.50) 126 0.35 (0.30–0.40)
<1 l 48 0.44 (0.36–0.54) 0.72 42 0.36 (0.28–0.47) 0.87
>1 l 24 0.41 (0.31–0.55) 49 0.37 (0.29–0.47)
BMI (kg/m2)
<25 82 0.41 (0.36–0.49) 55 0.33 (0.26–0.41)
25–29.9 69 0.49 (0.41–0.57) 0.44 46 0.38 (0.30–0.48) 0.59
>30 76 0.45 (0.38–0.52) 116 0.36 (0.31–0.42)
Comorbid condition
No 144 0.44 (0.38–0.48) 119 0.39 (0.34–0.46)
Yes 83 0.46 (0.41–0.55) 0.73 98 0.32 (0.26–0.38) 0.08
TB status
No history 73 0.45 (0.38–0.53) 0.93 191 0.36 (0.32–0.40) 0.80
Current/past 154 0.44 (0.40–0.50) 26 0.34 (0.25–0.48)
CI, confidence interval; TB, tuberculosis. MP value test for trend.
Table 4. (b) (Continued )
Variable N
HIV-infected participants
Mean CDKN2A P N
HIV-seronegative participants
Mean CDKN2A P
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‘survivor effects’ cannot be excluded. Individuals with
poor biological ageing may die earlier; thus, participants
comprise survivors with different biological character-
istics to nonsurvivors. However, recruitment of individ-
uals from similar socioeconomic backgrounds should
have limited potential confounding and survivor effects.
The differences in smoking and alcohol consumption
between the two groups could be due to HIV-infected
participants modifying their smoking and alcohol
consumption behaviours in response to lifestyle counsel-
ling. However, it is also plausible that the reported
differences are due to misclassification, with HIV-infected
participants wanting to demonstrate ‘healthy beha-
viour’, possibly leading to confounding. We used
location of work as a proxy measure of UV exposure,
which may also have been confounded by socio-
economic status. The sex composition of participants
was three-quarters female, consistent with the charac-
teristics of the clinic cohort from where our participants
were enumerated [47], and reflective of the African
AIDS epidemic. Lastly, as all our study participants are
of African ancestry, our results are only generalizable to
the African population.
The AIDS epidemic in sub-Saharan Africa is entering
a new phase wherein HIV-infected individuals are
living longer and may be ageing faster [9,48]. Our data
indicate increased biological ageing in HIV-infected
individuals compared with HIV-seronegative individ-
uals. The increased number of older HIV-infected
individuals in this region, compounded by accelerated
biological ageing, may have wide-ranging implica-
tions for HIV management. Delivery of healthcare
systems integrating HIV treatment and age-related
morbidity may be necessary to manage this phase of
the epidemic.
In light of these findings, important research questions
arise: prospective assessment of biological age in HIV-
infected and HIV-seronegative individuals is needed to
ascertain whether the accelerated ageing trajectory
develops as soon as HIV infection is acquired. Further
questions include whether biological age is dependent
upon the duration of untreated disease or nadir CD4þ cell
count, and if the biological age of the two groups
continues to diverge during long-term ART, or rather is
modified by ART. Finally, assessment of the relative
contributions of HIVand ART towards biological ageing
may provide mechanistic insight.
In summary, greater biological age, as determined by
shorter telomere length and higher CDKN2A expres-
sion, is associated with HIV infection in South Africa.
The ‘ageing of the HIVepidemic’ poses many challenges
and these may be amplified by accelerated biological
ageing, potentially resulting in important health and
social implications for the millions of patients receiving
ART in Africa.
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